Skip to content
Menu

Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $12

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $13 to $12.

Canaccord Genuity analyst Edward Nash maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $13 to $12.

Read at benzinga.com